Attention Deficit Disorder With Hyperactivity — Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
Citation(s)
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD)